Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 4/20 | 0.36 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.36 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.36 |
| ▸ | CYP51A1 | Q16850 | 5/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841859 | 1.00 | KCNA5 (0.36) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL4239507 | 0.93 | ADRB1 (0.31) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL4239510 | 0.93 | ADRB1 (0.31) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL4250387 | 0.90 | ADRB3 (0.33) | ADRB3ADRB1ADRB2CPB2AOC3 | |
| SCHEMBL12662932 | 0.88 | KCNA5 (0.34) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL14149054 | 0.82 | KCNA5 (0.34) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL4239457 | 0.80 | NOS3 (0.33) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL1842940 | 0.80 | KDM4E (0.34) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL1842366 | 0.80 | KDM4E (0.34) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL1842364 | 0.80 | KDM4E (0.34) | KCNA5KCNJ5KCNJ3SCN5AKCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
| EP-2104503-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2009-09-30 | — | — | EP | disclosed |
| US-7576081-B2 | Central nervous system disorders ; sexual disorders; hypotensive agents; analgesics; neurodegenerative disease; obesity; Alzheimer's disease; obsessive compulsive disorders; antidepressants | PFIZER INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2008087512-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2008-07-24 | — | — | WO | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060235016-A1 | Morpholine Dopamine Agonists | PFIZER INC | 2006-10-19 | — | — | US | disclosed |
| EP-1572214-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-20040259874-A1 | Morpholine dopamine agonists | PFIZER INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004052372-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235016-A1 | Morpholine Dopamine Agonists | DBH, OPRM1, ADRA2B | KCNA5 741/4885KCNJ5 1562/4885KCNJ3 1391/4885 |
| US-20040259874-A1 | Morpholine dopamine agonists | DBH, OPRM1, OPRD1 | KCNA5 427/4885KCNJ5 1674/4885KCNJ3 1536/4885 |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | DBH, OPRM1, CHRM1 | KCNA5 800/4885KCNJ5 1683/4885KCNJ3 1482/4885 |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | OPRL1, OPRD1, OPRK1 | KCNA5 311/4885KCNJ5 555/4885KCNJ3 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.